In a targeted night operation in Borno state, Nigerian troops neutralized a high-ranking Boko Haram leader and ten fighters, marking a significant blow to the militant group's command structure in its historic stronghold.
Wildfires ravaging Argentina's Patagonia region have breached a UNESCO World Heritage site, fueling a political firestorm over President Javier Milei's deep cuts to environmental and emergency funding.
Insiders at Canadian forestry giant Canfor Corporation have been net buyers of the company's shares over the last twelve months, with President Susan Yurkovich leading the activity. The trend signals internal optimism as key executives invest personal capital even above current trading prices.
Despite posting a quarterly loss in its core wood products unit amid 'extremely challenging' markets, Weyerhaeuser closed 2025 with strategic pivots. The forestry giant is doubling down on its land management and nascent 'Climate Solutions' business, while managing a disciplined capital return to shareholders.
For the second year running, a Chicago financial institution has become the nation's first bank failure. Regulators shuttered Metropolitan Capital Bank & Trust on Friday, citing unsafe practices and depleted capital. The FDIC facilitated a swift takeover by Detroit's First Independence Bank, ensuring depositors are protected.
An AI-driven analysis suggests Cloudflare (NET) shares may face headwinds over the next two months, projecting an average price near $168. The forecast contrasts with bullish long-term analyst views, highlighting the tension between immediate technical signals and the company's strategic positioning in edge security and AI infrastructure.
While Broadcom rides a massive wave of AI demand, investor concerns over shrinking profitability have triggered a significant pullback in its shares, presenting a classic growth-versus-margin dilemma.
A deep dive into the software company's valuation using a discounted cash flow model suggests its shares may be trading at a significant premium to their estimated intrinsic value.
A coalition of environmental groups is sounding the alarm over two massive Royal Caribbean developments in Cozumel and Mahahual, warning of severe ecological strain and social disruption, as legal challenges begin to mount.
Amid market volatility driven by AI speculation, a seasoned investor makes the case for a dual-anchor strategy built on Apple's surging iPhone sales and Berkshire Hathaway's formidable $378 billion cash reserve.
While Colgate-Palmolive's stock has trailed the S&P 500 over the past year, Wall Street analysts see a resilient business model and strong international presence supporting long-term growth, maintaining a 'Moderate Buy' consensus.
Despite a sharp sell-off in its shares, HubSpot reports a surge in new contract signings and projects an expanding free cash flow margin, signaling underlying operational strength even as investors remain wary.
Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.
Despite a modest price target reduction, Morgan Stanley reaffirms its Overweight rating on Wingstop, citing the chicken wing chain's robust unit expansion and system-wide sales momentum as key drivers for its 2026 outlook.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Goldman Sachs Group (GS) has approved a significant dividend increase and projects a robust earnings outlook for Corporate America, fueling debate over whether its strong share price momentum has outpaced its fundamental valuation.
Amid a sluggish housing sector, Installed Building Products (IBP) has demonstrated remarkable resilience, becoming a standout performer in Giverny Capital's portfolio. The insulation specialist's shares have surged over 50% in the past year, bucking broader market trends.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
